The key role of IL-5 in eosinophil production and function has made this cytokine a prime therapeutic target. This has been reinforced by results in animal models of asthma showing that deletion of the IL-5 gene (1) or the use of IL-5-neutralizing antibodies (2) is able to suppress eosinophil recruitment to the lung and, in many but not all cases (3), inhibit hyper-responsiveness of the airways to agents that induce bronchoconstriction, a characteristic feature of allergic asthma. Double eotaxin-1/IL-5 gene-deleted mice exhibited a greater suppression of eosinophil recruitment to the lung and the abolition of airway hyper-responsiveness associated, interestingly, with reduced IL-13 production (4).
Animal studies, particularly those in allergic cynomolgus monkeys showing long-term inhibition of lung eosinophilia and airway hyperresponsiveness by a single dose of an anti-IL-5 antibody (5), encouraged the initiation of clinical trials in which antibody was administered to mild atopic asthmatics (6) and chronic severe asthmatics (7) . These studies showed no consistent effects on lung function tests, despite a marked suppression of blood eosinophils. From the results of these studies, some concluded that eosinophils are not causally related to lung dysfunction, although the results are contentious, particularly because of the small size of the trials and their technical limitations (8, 9) . Furthermore, a followup study of bronchial biopsies from antibody-treated patients showed that despite marked depletion of blood and sputum eosinophils, airway tissue eosinophils were only depleted by 55% (10), suggesting that the residual cells could be important in lung dysfunction.
The eosinophil in tissue remodeling
The finding that eosinophils are able to produce growth factors directed attention to the potential role of these cells in the resolution of inflammation Eosinophils accumulate in high numbers in the lungs of asthmatic patients. These cells have the ability to induce tissue damage, a capacity that relates to their traditional role in host defense against parasitic worms. On the other hand, eosinophils produce growth factors associated with tissue repair and remodeling, notably TGF-β 1 . The relationship of these activities to lung dysfunction in asthma is highly controversial, but recent observations in humans and in animal models add spice to the debate (see the related article beginning on page 551). and tissue repair. Tissue eosinophilia is a characteristic feature of several fibrotic diseases, and these cells are implicated in the remodeling that occurs in allergic asthma. Remodeling manifests itself in the airway wall as an increased deposition of extracellular matrix proteins in the reticular basement membrane and bronchial submucosa, an increase in smooth muscle mass, goblet cell hyperplasia, and angiogenesis. Eosinophils are capable of producing TGF-α, TGF-β 1 , and VEGF, as well as a range of cytokines, including IL-13.
Evidence from animal models supports the view that eosinophils have an important role in tissue remodeling. An antibody to IL-5 (11) and IL-5 gene deletion (12) have been shown to suppress lung eosinophilia and components of lung remodeling in murine models of allergic asthma. In this issue of the JCI, the study by Cho et al. (13) investigates the relationship between eosinophils and tissue remodeling in detail. They show in a chronic repetitive allergen challenge model that IL-5 gene deletion suppresses lung eosinophilia and tissue remodeling in parallel. Specifically, IL-5-deficient mice exhibited reduced eosinophil numbers in bronchoalveolar lavage fluid (BALF) and in peribronchial tissue. This was associated with decreased TGF-β 1 content of lung tissue with evidence that eosinophils were the major source of the growth factor. Interestingly, the epithelial cell expression of α v β 6 , the integrin that is upregulated in response to tissue injury and activates latent TGF-β 1 (14, 15) , was also suppressed. Allergen-induced increase in peribronchial fibrosis, as measured by trichrome staining, collagen III and collagen V immunostaining, and total lung collagen content, was reduced in IL-5-deficient animals. Peribronchial smooth muscle thickness and epithelial mucus expression were also reduced.
These results echo observations made in humans. It has been shown that eosinophil-derived TGF-β 1 is associated with the transformation of fibroblasts to myofibroblasts and the expression by these cells of tenascin and procollagen I in allergic responses in human skin (16) (Figure 1) . Furthermore, treatment of asthmatic patients with an antibody to IL-5 suppressed bronchial eosinophilia, the proportion of eosinophils expressing TGF-β 1 , and the levels of TGF-β 1 in BALF (17) . The expression of tenascin, lumican, and procollagen III in bronchial mucosal reticular basement membrane was also reduced (17) .
The eosinophil as a therapeutic target All these observations suggest that the eosinophil, despite its checkered history, does make an important contribution to the pathology of allergic asthma. The effect of IL-5 neutralization or gene deletion on lung function varies between animal models (perhaps indicating different underlying mechanisms depending on experimental protocol), and such an effect using antibodies to IL-5 in humans has yet to be convincingly demonstrated. It may be that prolonged treatment targeted toward eosinophils may have an impact on symptoms as a consequence of suppression of alternating cycles of tissue damage and repair. If so, this will present a challenge in the design of appropriate clinical trials and prompt a reevaluation of biomarkers. An early study in guinea pigs showed that an antibody to IL-5 effectively suppressed allergen-induced BALF eosinophilia to low levels without affecting hyperresponsiveness, whereas higher antibody doses blocked hyper-responsiveness (18) . This may relate to the recent clinical observations of residual eosinophils in lung tissue, or it may indicate actions of IL-5 that are independent of eosinophils. Either way, the doses of antibody used in published clinical trials may not have been high enough to demonstrate effects on lung function.
The studies discussed here may revive interest in other means of preventing eosinophil recruitment, particularly using chemokine receptor 3 antagonists. Combinations aimed at chemokines and IL-5 are attractive, but present considerable difficulties in testing and development.
Thus, the eosinophil appears to have the capacity to both injure and repair tissues, presumably related to its perceived traditional role in host defense. Knowledge of the underlying mechanisms may yet lead to therapy for allergic diseases, despite early setbacks. Acknowledgments T.J. Williams is the National Asthma Campaign Professor of Applied Pharmacology at Imperial College London.
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Figure 1
Role of eosinophil-derived TGF-β 1 in lung remodeling. Eosinophils in the asthmatic lung release latent TGF-β 1 . Latent TGF-β 1 (latTGF-β 1 ) is activated by α v β 6 expressed on airway epithelial cells. TGF-β 1 mediates airway remodeling by inducing the formation of myofibroblasts that secrete extracellular matrix proteins, and the growth factor also stimulates airway smooth muscle hyperplasia.
